

Open camera or QR reader and  
scan code to access this article  
and other resources online.



# Defucosylated Mouse-Dog Chimeric Anti-Human Epidermal Growth Factor Receptor 2 Monoclonal Antibody (H77Bf) Exerts Antitumor Activities in Mouse Xenograft Models of Canine Osteosarcoma

Ren Nanamiya,<sup>1,\*</sup> Tomokazu Ohishi,<sup>2,\*</sup> Hiroyuki Suzuki,<sup>3</sup> Takuya Mizuno,<sup>4</sup> Takeo Yoshikawa,<sup>5</sup> Teizo Asano,<sup>1</sup> Tomohiro Tanaka,<sup>1</sup> Mika K. Kaneko,<sup>1</sup> and Yukinari Kato<sup>1,3,5</sup>

Human epidermal growth factor receptor 2 (HER2) has been studied in many human cancer types, and its overexpression and/or gene mutation contribute to the poor prognosis. Therefore, HER2 is an important therapeutic target in various cancer types, including breast and gastric cancers. We previously developed an anti-HER2 monoclonal antibody (mAb), H<sub>2</sub>Mab-77 (mouse IgG<sub>1</sub>, kappa), which detects HER2 and dog HER2 (dHER2) with high sensitivity and specificity. In this study, we produced a defucosylated mouse-dog chimeric anti-HER2 mAb (H77Bf), and investigated the reactivity against canine osteosarcoma D-17 cells by flow cytometry. Furthermore, we showed that H77Bf exerted antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity against D-17 cells *in vitro* and exhibited the potent antitumor activity *in vivo*. These results suggest that H77Bf exerts antitumor effects against dHER2-expressing canine tumors and could be valuable as part of an antibody treatment regimen for them.

**Keywords:** HER2, mouse-dog chimeric antibody, ADCC, CDC, canine osteosarcoma, antitumor activity

## Introduction

**H**UMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2) is a type-I transmembrane glycoprotein and member of receptor tyrosine kinases. HER2 overexpression is reported in many human cancers, including breast cancer,<sup>1,2</sup> gastric cancer,<sup>3</sup> colorectal cancer,<sup>4</sup> lung adenocarcinoma,<sup>5</sup> and osteosarcoma (OS).<sup>6-8</sup> Overexpression of HER2 results in homo- or heterodimerization of the HER family members, which leads to autophosphorylation of tyrosine residues in the cytoplasmic domains. The tyrosine phosphorylation initiates signaling transductions including Ras-MEK-ERK and PI3 kinase-AKT pathways, which play critical roles in tumor cell proliferation, invasion, and tumorigenesis.<sup>9,10</sup>

Trastuzumab, a monoclonal antibody (mAb) targeting HER2, has improved survival rates in HER2-positive advanced and early-stage breast cancer, and has been the most effective therapy for HER2-positive breast cancer.<sup>11-15</sup> The recently developed trastuzumab deruxtecan (DS-8201) contains a novel enzyme cleavable-linker and a topoisomerase I inhibitor, deruxtecan as a payload.<sup>16</sup> Although there is no established regimen for patients with HER2-positive non-small cell lung cancer (NSCLC), the promising efficacy of DS-8201 in patients with HER2-mutant NSCLC has been reported.<sup>17</sup>

HER2 is also overexpressed in multiple canine cancers, including OS,<sup>18</sup> anal sac gland carcinoma,<sup>19</sup> mammary carcinoma,<sup>20</sup> and bladder transitional cell carcinoma.<sup>21</sup> Fazekas

<sup>1</sup>Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.

<sup>2</sup>Institute of Microbial Chemistry (BIKAKEN), Numazu, Microbial Chemistry Research Foundation, Numazu-shi, Shizuoka, Japan.

<sup>3</sup>Department of Molecular Pharmacology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.

<sup>4</sup>Laboratory of Molecular Diagnostics and Therapeutics, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan.

<sup>5</sup>Department of Pharmacology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.

\*Contributed equally to this study.

et al conducted a clinical trial using the HER2 vaccine in a spontaneous HER2-positive canine mammary carcinoma to evaluate the safety and efficacy.<sup>22</sup> In a phase I study in canine OS, administration of a *Listeria* vaccine expressing chimeric HER2 induced dog HER2 (dHER2)-specific immunity, suppressed the development of metastases, and prolonged survival.<sup>23</sup> Therefore, dHER2 could be a promising therapeutic treatment of canine cancers.

We previously developed anti-HER2 mAbs, including H<sub>2</sub>Mab-19,<sup>24–27</sup> H<sub>2</sub>Mab-41,<sup>28,29</sup> H<sub>2</sub>Mab-77,<sup>30</sup> H<sub>2</sub>Mab-119,<sup>31</sup> H<sub>2</sub>Mab-139,<sup>32</sup> and H<sub>2</sub>Mab-181,<sup>33,34</sup> which detect not only HER2 but also dHER2. This study aimed to investigate the ability of a defucosylated mouse-dog chimeric H<sub>2</sub>Mab-77 (H77Bf) to induce antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antitumor activities against a canine OS cell line, which endogenously expresses dHER2.

## Materials and Methods

### Cell lines

D-17, a canine OS cell line,<sup>35,36</sup> was obtained from the American Type Culture Collection (Manassas, VA). D-17 was cultured in minimum essential media (Nacalai Tesque, Inc., Kyoto, Japan), supplemented with 10% heat-inactivated fetal bovine serum (FBS; Thermo Fisher Scientific Inc., Waltham, MA), 1 mM of sodium pyruvate, 100 U/mL of penicillin, 100 µg/mL streptomycin, and 0.25 µg/mL amphotericin B (Nacalai Tesque, Inc.). The cells were cultured at 37°C in a humidified atmosphere with 5% carbon dioxide.

### Antibodies

An anti-HER2 mAb, H<sub>2</sub>Mab-77, was established in our laboratory as previously described.<sup>30</sup> To generate H77B, we subcloned V<sub>H</sub> cDNA of H<sub>2</sub>Mab-77 and C<sub>H</sub> of dog IgGB into the pCAG-Ble vector (FUJIFILM Wako Pure Chemical Corporation, Osaka, Japan), along with V<sub>L</sub> cDNA of H<sub>2</sub>Mab-77 and C<sub>L</sub> cDNA of dog kappa light chain into the pCAG-Neo vector (FUJIFILM Wako Pure Chemical Corporation), respectively. The vector of H77B was transfected into BINDS-09 cells (FUT8-deficient ExpiCHO-S cells)<sup>37–43</sup> using the ExpiCHO Expression System (Thermo Fisher Scientific Inc.). The resulting mAb, H77Bf, was purified with Protein G-Sepharose (GE Healthcare Biosciences, Pittsburgh, PA). Dog IgG was commercially purchased from Jackson ImmunoResearch Inc. (West Grove, PA).

### Animals

All animal experiments were carried out following relevant guidelines and regulations to minimize animal suffering and distress in the laboratory. Animal experiments for testing antitumor activity were approved by the Institutional Committee for Experiments of the Institute of Microbial Chemistry (permit no. 2021-056). Mice were kept in a specific pathogen-free environment (23°C ± 2°C, 55% ± 5% humidity) on an 11-hour light/13-hour dark cycle with food and water supplied *ad libitum* across the experimental period. Mice were monitored for health and weight every 2–5 days during the 3-week period of each experiment. We determined the loss of original body weight to a point >25% and/or a

maximum tumor size >2000 mm<sup>3</sup> as humane endpoints for euthanasia. Mice were euthanized by cervical dislocation; death was confirmed by respiratory and cardiac arrest.

### Flow cytometry

D-17 cells were harvested by brief exposure to 0.25% trypsin/1 mM ethylenediamine tetraacetic acid (EDTA; Nacalai Tesque, Inc.). After washing with blocking buffer of 0.1% bovine serum albumin in phosphate-buffered saline (PBS), cells were treated with H77Bf or control blocking buffer for 30 minutes at 4°C. Subsequently, the cells were incubated in fluorescein isothiocyanate (FITC)-conjugated anti-dog IgG at a dilution of 1:1000 (Thermo Fisher Scientific Inc.) for 30 minutes at 4°C. Fluorescence data were collected using the EC800 Cell Analyzer (Sony Corp., Tokyo, Japan).

### Determination of the binding affinity

D-17 cells were suspended in 100 µL of serially diluted H77Bf (0.006–25 µg/mL) followed by FITC-conjugated anti-dog IgG (1:200). Fluorescence data were collected using the EC800 Cell Analyzer. The dissociation constant ( $K_D$ ) was calculated by fitting binding isotherms to built-in one-site binding models in GraphPad Prism 8 (GraphPad Software, Inc., La Jolla, CA).

### ADCC of H77Bf

Canine mononuclear cells (MNCs) were obtained from Yamaguchi University and suspended in Dulbecco's modified Eagle medium (DMEM; Nacalai Tesque, Inc.) with 10% FBS to be used as effector cells. Target cells were labeled with 10 µg/mL Calcein AM (Thermo Fisher Scientific, Inc.) and resuspended in the same medium. The target cells ( $2 \times 10^4$  cells/well) were plated in 96-well plates and mixed with effector cells (effector/target cells ratio, 50), 100 µg/mL of H77Bf or control dog IgG. After 4.5 hours incubation at 37°C, the release of Calcein into the supernatant was measured in each well.

The fluorescence intensity was determined using a microplate reader (Power Scan HT; BioTek Instruments, Inc., Winooski, VT) with an excitation wavelength of 485 nm and an emission wavelength of 538 nm. Cytolytic activity (% lysis) was calculated as follows: % lysis =  $(E - S)/(M - S) \times 100$ , where "E" is the fluorescence measured in combined cultures of target and effector cells, "S" is the spontaneous fluorescence of target cells only, and "M" is the maximum fluorescence measured after the lysis of all cells with a buffer containing 0.5% Triton X-100, 10 mM Tris-HCl (pH 7.4), and 10 mM EDTA.

### CDC of H77Bf

The target cells were labeled with 10 µg/mL Calcein AM and resuspended in the medium. Then, they were plated in 96-well plates at  $2 \times 10^4$  cells/well with rabbit complement (final dilution 1:10; Low-Tox-M Rabbit Complement; Cedarlane Laboratories, Hornby, Ontario, Canada) and 100 µg/mL of H77Bf or control dog IgG. After 4.5 hours of incubation at 37°C, we measured Calcein release into the supernatant for each well. Fluorescence intensity was calculated as described in the ADCC section earlier.

### Antitumor activity of H77Bf in mouse xenograft models of D-17 cells

A total of 16 female BALB/c nude mice (5 weeks old, weighing 14–17 g) were purchased from Charles River Laboratories, Inc. and used in experiments once they reached 8 weeks of age. D-17 cells ( $0.3\text{ mL}$  of  $1.33 \times 10^8$  cells/mL in DMEM) were mixed with  $0.5\text{ mL}$  BD Matrigel Matrix Growth Factor Reduced (BD Biosciences, San Jose, CA);  $100\text{ }\mu\text{L}$  of this suspension ( $5 \times 10^6$  cells) was injected subcutaneously into the left flanks of the mice. On day 8 post-inoculation,  $100\text{ }\mu\text{g}$  of H77Bf ( $n=8$ ) or control dog IgG ( $n=8$ ) in  $100\text{ }\mu\text{L}$  PBS were injected intraperitoneally. Additional antibody inoculations were performed on days 14 and 21. MNCs were injected surrounding the tumors on days 8, 14, and 21. The tumor volume was measured on days 7, 10, 14, 17, 21, 24, and 28 after the injection of cells. At 28 days after cell implantation, all mice were euthanized by cervical dislocation. Tumor diameters and volumes were measured as previously described.<sup>35,36,44,45</sup>


### Statistical analyses

All data are expressed as mean  $\pm$  standard error of the mean. All statistical analyses were carried out with Welch's *t*-test for ADCC, CDC, and tumor weight. Sidak's multiple comparisons tests were conducted for tumor volume and mouse weight. All calculations were performed using GraphPad Prism 8. A *p*-value  $<0.05$  is statistically significant.

### Results

#### Flow cytometric analysis against canine OS D-17 cells using H77Bf

An anti-HER2 mAb, H<sub>2</sub>Mab-77, was previously established by immunizing mice with ectodomain of HER2.<sup>30</sup> We next generated H77Bf, a defucosylated mouse-dog chimeric anti-HER2 mAb by combining V<sub>H</sub> and V<sub>L</sub> of H<sub>2</sub>Mab-77 with C<sub>H</sub> and C<sub>L</sub> of dog IgG, respectively. We investigated the reactivity of H77Bf against canine OS D-17 cells, and found that H77Bf could detect endogenous dHER2 in D-17 cells (Fig. 1A).




**FIG. 1.** Flow cytometry using H77Bf and evaluation of ADCC and CDC. **(A)** D-17 cells were treated with H77Bf (10–0.01  $\mu\text{g}/\text{mL}$ ), followed by secondary antibodies. **(B)** Determination of the binding affinity of H77Bf for D-17 cells using flow cytometry. D-17 cells were suspended in  $100\text{ }\mu\text{L}$  of serially diluted H77Bf, followed by the addition of FITC-conjugated anti-dog IgG. Fluorescence data were collected using the EC800 Cell Analyzer. **(C, D)** ADCC **(C)** and CDC **(D)** elicited by H77Bf and control dog IgG targeting D-17 cells. The values shown are the means  $\pm$  SEM. Asterisks indicate statistical significance ( $*p < 0.05$ ; Welch's *t*-test). ADCC, antibody-dependent cellular cytotoxicity; CDC, complement-dependent cytotoxicity; FITC, fluorescein isothiocyanate; SEM, standard error of the mean.

A kinetic analysis of the interactions of H77Bf with D-17 cells was carried out using flow cytometry. The  $K_D$  for the interaction of H77Bf with D-17 cells was  $6.7 \times 10^{-10}$  M (Fig. 1B), demonstrating that H77Bf has high affinity for D-17 cells.

#### H77Bf-mediated ADCC and CDC in D-17 cells

We investigated whether H77Bf mediated ADCC against D-17 cells. As shown in Figure 1C, H77Bf showed ADCC (10.4% cytotoxicity;  $p < 0.05$ ) against D-17 cells more effectively than did the control dog IgG (3.4% cytotoxicity).




**FIG. 2.** Evaluation of antitumor activity of H77Bf in D-17 xenograft models. **(A)** D-17 cells ( $5 \times 10^6$  cells) were injected subcutaneously into the left flank. On day 8, 100  $\mu$ g of H77Bf or control dog IgG in 100  $\mu$ L PBS were injected intraperitoneally into mice; additional antibodies were then injected on days 14 and 21. The tumor volume was measured on days 7, 10, 14, 17, 21, 24, and 28 after the injection. Values shown are the means  $\pm$  SEM. Asterisks indicate statistical significance (\*\* $p < 0.01$ , \* $p < 0.05$ ; ANOVA and Sidak's multiple comparisons test). **(B)** Tumors of D-17 xenografts were resected from H77Bf and control dog IgG groups. Tumor weight on day 28 was measured from excised xenografts. Values are mean  $\pm$  SEM. Asterisk indicates statistical significance (\*\* $p < 0.01$ , Welch's  $t$ -test). **(C)** Resected tumors of D-17 xenografts from control dog IgG and H77Bf groups on day 28. Scale bar, 1 cm. ANOVA, analysis of variance; PBS, phosphate-buffered saline.

Subsequently, we investigated whether H77Bf mediated CDC against D-17 cells. As shown in Figure 1D, H77Bf showed CDC (68.4% cytotoxicity;  $p < 0.05$ ) against D-17 cells more highly than did the control dog IgG (53.3% cytotoxicity). These results indicated that H77Bf promoted significantly higher levels of ADCC and CDC against endogenous dHER2-expressing D-17 cells.

#### Antitumor activities of H77Bf in the mouse xenograft models of D-17 cells

In the D-17 mouse xenograft models, H77Bf (100  $\mu$ g) and control dog IgG (100  $\mu$ g) were injected intraperitoneally into mice on days 8, 14, and 21, after the injection of D-17 cells. The tumor volume was measured on days 7, 10, 14, 17, 21, 24, and 28 after the injection of the cells. H77Bf treatment significantly suppressed tumor development on days 14 ( $p < 0.05$ ), 17 ( $p < 0.01$ ), 21 ( $p < 0.01$ ), 24 ( $p < 0.01$ ), and 28 ( $p < 0.01$ ) compared with that of the control dog IgG (Fig. 2A). The administration of H77Bf resulted in a 62% reduction of tumor mass compared with that of the control dog IgG on day 28 postinoculation. Furthermore, tumors



**FIG. 3.** Body weights and appearance of the mice implanted with D-17 xenograft models. **(A)** Body weights of the mice implanted with D-17 xenograft models were recorded on days 7, 10, 14, 17, 21, 24, and 28. **(B)** Body appearance of mice on day 28. Values shown are the means  $\pm$  SEM. Scale bar, 1 cm. n.s., not significant.

from the H77Bf-treated mice weighed significantly less than those from the control dog IgG-treated mice (60% reduction;  $p < 0.01$ , Fig. 2B). Tumors removed from mice on day 28 are shown in Figure 2C. Total body weights did not differ significantly among the two groups (Fig. 3A). The body appearance of mice on day 28 are shown in Figure 3B.

Taken together, these results indicated that the administration of H77Bf effectively reduced the growth of D-17 xenografts.

## Discussion

OS is the most frequent primary bone cancer in dogs. Eighty percent of dogs with OS is lethal due to the lung metastasis.<sup>46</sup> Selvarajah et al reported that the epidermal growth factor receptor (EGFR) expression was significantly upregulated in OS lung metastasis compared with extrapulmonary sites.<sup>47</sup> The rate of OS in dogs is 27 times higher than that in humans, with a 1-year survival rate of only 45%.<sup>48</sup> Currently, treatment options for OS in dogs include surgery (limb amputation or limb-sparing surgery), radiation therapy, and chemotherapy.<sup>49,50</sup> However, satisfied therapeutic efficacies have not been obtained. Hence, the development of other therapeutic options for canine OS is necessary.

Antibody therapy is widely used for human diseases including cancers and immune disorders. The caninization of mAbs such as Lokivetmab<sup>51</sup> is essential for developing antibody therapies for dogs. However, caninized mAbs for canine cancers have not been developed yet. Thus, the development of the mAbs for canine cancer treatment is needed.

The amino acid sequences are similar between human and dog about EGFR and HER2; in contrast, low homology was observed between human and dog about CD20 and programmed-cell death ligand 1.<sup>52–54</sup> Therefore, anti-human EGFR or anti-HER2 mAbs could be applicable to canine cancers. Indeed, cetuximab (anti-human EGFR mAb) and trastuzumab exhibited growth inhibitory effect by interfering dog EGFR (dEGFR) and dHER2 signaling, respectively.<sup>52</sup> We also have been investigating the cross-reactivity of our established anti-human EGFR mAb (EMab-134) to dEGFR<sup>35,36,44,45</sup> and another anti-HER2 mAb (H<sub>2</sub>Mab-41) to dHER2.<sup>29</sup>

Our study demonstrated that H77Bf significantly exhibited ADCC and CDC activities in canine OS D-17 cells compared with dog IgG *in vitro* (Fig. 1C, D). One of the most important objectives of this study was to investigate the antitumor activity of H77Bf for endogenous dHER2-expressing canine tumor cells *in vivo*. H77Bf administration showed the potent antitumor effect on endogenous dHER2-expressing D-17 cells without body weight loss and skin disorders (Figs. 2 and 3).

These results indicate that H77Bf could be useful for an antibody therapeutic regimen for dHER2-positive canine OS. Moreover, H<sub>2</sub>Mab-77, which is the origin of H77Bf, is applicable for immunohistochemistry<sup>30</sup>; therefore, we need to investigate whether H77Bf detects endogenous dHER2 in canine OS tissues to evaluate usefulness of H77Bf as a diagnostic mAb for immunohistochemistry. Future studies are necessary to test the antitumor activity of H77Bf on other several types of endogenous dHER2-expressing canine cancers *in vivo* animal experimental models.

## Author Disclosure Statement

No competing financial interests exist.

## Funding Information

This research was supported in part by Japan Agency for Medical Research and Development (AMED) under Grant Numbers: JP22ama121008 (to Y.K.), JP22am0401013 (to Y.K.), JP22bm1004001 (to Y.K.), JP22ck0106730 (to Y.K.), and JP21am0101078 (to Y.K.), and by the Japan Society for the Promotion of Science (JSPS) Grants-in-Aid for Scientific Research (KAKENHI) grant nos. 22K15523 (to T.A.), 21K20789 (to T.T.), 22K06995 (to H.S.), 22K07168 (to M.K.K.), and 22K07224 (to Y.K.).

## References

- Howlader N, Altekruse SF, Li CI, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. *J Natl Cancer Inst* 2014;106(5):dju055; doi: 10.1093/jnci/dju055
- Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. *Science* 1987;235:177–182; doi: 10.1126/science.3798106
- Xie S, Zhang H, Wang X, et al. The relative efficacy and safety of targeted agents used in combination with chemotherapy in treating patients with untreated advanced gastric cancer: A network meta-analysis. *Oncotarget* 2017; 8:26959–26968; doi: 10.18632/oncotarget.15923
- Seo AN, Kwak Y, Kim DW, et al. HER2 status in colorectal cancer: Its clinical significance and the relationship between HER2 gene amplification and expression. *PLoS One* 2014;9:e98528; doi: 10.1371/journal.pone.0098528
- Kim EK, Kim KA, Lee CY, et al. The frequency and clinical impact of HER2 alterations in lung adenocarcinoma. *PLoS One* 2017;12:e0171280; doi: 10.1371/journal.pone.0171280
- Onda M, Matsuda S, Higaki S, et al. ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma. *Cancer* 1996;77:71–78; doi: 10.1002/(SICI)1097-0142(1996101)77:1 <71::AID-CNCR13>3.0.CO;2–5
- Gorlick R, Huvos AG, Heller G, et al. Expression of HER2/erbB-2 correlates with survival in osteosarcoma. *J Clin Oncol* 1999;17:2781–2788; doi: 10.1200/JCO.1999.17.9.2781
- Scotlandi K, Manara MC, Hattinger CM, et al. Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma. *Eur J Cancer* 2005;41: 1349–1361; doi: 10.1016/j.ejca.2005.03.015
- Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. *Nat Rev Mol Cell Biol* 2001;2:127–137; doi: 10.1038/35052073
- Krishnamurti U, Silverman JF. HER2 in breast cancer: A review and update. *Adv Anat Pathol* 2014;21:100–107; doi: 10.1097/PAP.000000000000015
- Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. *N Engl J Med* 2001;344:783–792; doi: 10.1056/NEJM200103153441101
- Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. *N Engl J Med* 2011; 365:1273–1283; doi: 10.1056/NEJMoa0910383
- Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive

- breast cancer: A randomised controlled trial. *Lancet* 2007; 369:29–36; doi: 10.1016/S0140-6736(07)60028-2
14. Okines AF, Cunningham D. Trastuzumab: A novel standard option for patients with HER-2-positive advanced gastric or gastro-oesophageal junction cancer. *Therap Adv Gastroenterol* 2012;5:301–318; doi: 10.1177/1756283X12450246
  15. Oh DY, Bang YJ. HER2-targeted therapies - a role beyond breast cancer. *Nat Rev Clin Oncol* 2020;17:33–48; doi: 10.1038/s41571-019-0268-3
  16. Doi T, Shitara K, Naito Y, et al. Safety, pharmacokinetics, and antitumor activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: A phase 1 dose-escalation study. *Lancet Oncol* 2017;18:1512–1522; doi: 10.1016/S1470-2045(17)30604-6
  17. Li BT, Smit EF, Goto Y, et al. Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer. *N Engl J Med* 2022;386:241–251; doi: 10.1056/NEJMoa2112431
  18. Flint AF, U'Ren L, Legare ME, et al. Overexpression of the erbB-2 proto-oncogene in canine osteosarcoma cell lines and tumors. *Vet Pathol* 2004;41:291–296; doi: 10.1354/vp.41-3-291
  19. Yoshimoto S, Kato D, Kamoto S, et al. Detection of human epidermal growth factor receptor 2 overexpression in canine anal sac gland carcinoma. *J Vet Med Sci* 2019;81:1034–1039; doi: 10.1292/jvms.19-0019
  20. Gama A, Alves A, Schmitt F. Identification of molecular phenotypes in canine mammary carcinomas with clinical implications: Application of the human classification. *Virchows Arch* 2008;453:123–132; doi: 10.1007/s00428-008-0644-3
  21. Millanta F, Impellizeri J, McSherry L, et al. Overexpression of HER-2 via immunohistochemistry in canine urinary bladder transitional cell carcinoma—A marker of malignancy and possible therapeutic target. *Vet Comp Oncol* 2018;16:297–300; doi: 10.1111/vco.12345
  22. Fazekas J, Furdos I, Singer J, et al. Why man's best friend, the dog, could also benefit from an anti-HER-2 vaccine. *Oncol Lett* 2016;12:2271–2276; doi: 10.3892/ol.2016.5001
  23. Mason NJ, Gnanandarajah JS, Engiles JB, et al. Immunotherapy with a HER2-targeting listeria induces HER2-specific immunity and demonstrates potential therapeutic effects in a phase I trial in canine osteosarcoma. *Clin Cancer Res* 2016;22:4380–4390; doi: 10.1158/1078-0432.CCR-16-0088
  24. Kato Y, Ohishi T, Sano M, et al. H2Mab-19 anti-human epidermal growth factor receptor 2 monoclonal antibody therapy exerts antitumor activity in pancreatic cancer xenograft models. *Monoclon Antib Immunodiagn Immunother* 2020;39:61–65; doi: 10.1089/mab.2020.0011
  25. Kato Y, Ohishi T, Takei J, et al. An antihuman epidermal growth factor receptor 2 monoclonal antibody (H2Mab-19) exerts antitumor activity in glioblastoma xenograft models. *Monoclon Antib Immunodiagn Immunother* 2020;39:135–139; doi: 10.1089/mab.2020.0013
  26. Kato Y, Ohishi T, Takei J, et al. An anti-human epidermal growth factor receptor 2 monoclonal antibody H2Mab-19 exerts antitumor activity in mouse colon cancer xenografts. *Monoclon Antib Immunodiagn Immunother* 2020;39:123–128; doi: 10.1089/mab.2020.0009
  27. Takei J, Kaneko MK, Ohishi T, et al. H2Mab-19, an anti-human epidermal growth factor receptor 2 monoclonal antibody exerts antitumor activity in mouse oral cancer xenografts. *Exp Ther Med* 2020;20:846–853; doi: 10.3892/etm.2020.8765
  28. Kato Y, Ohishi T, Yamada S, et al. Anti-human epidermal growth factor receptor 2 monoclonal antibody H2Mab-41 exerts antitumor activity in a mouse xenograft model of colon cancer. *Monoclon Antib Immunodiagn Immunother* 2019;38:157–161; doi: 10.1089/mab.2019.0017
  29. Tateyama N, Asano T, Ohishi T, et al. An anti-HER2 monoclonal antibody H2Mab-41 exerts antitumor activities in mouse xenograft model using dog HER2-overexpressed cells. *Monoclon Antib Immunodiagn Immunother* 2021;40:184–190; doi: 10.1089/mab.2021.0025
  30. Itai S, Fujii Y, Kaneko MK, et al. H2Mab-77 is a sensitive and specific anti-HER2 monoclonal antibody against breast cancer. *Monoclon Antib Immunodiagn Immunother* 2017;36:143–148; doi: 10.1089/mab.2017.0026
  31. Yamada S, Itai S, Nakamura T, et al. Establishment of H2Mab-119, an anti-human epidermal growth factor receptor 2 monoclonal antibody, against pancreatic cancer. *Monoclon Antib Immunodiagn Immunother* 2017;36:287–290; doi: 10.1089/mab.2017.0050
  32. Kaneko MK, Yamada S, Itai S, et al. Development of an anti-HER2 monoclonal antibody H2Mab-139 against colon cancer. *Monoclon Antib Immunodiagn Immunother* 2018;37:59–62; doi: 10.1089/mab.2017.0052
  33. Asano T, Takei J, Suzuki H, et al. Epitope mapping of an anti-HER2 monoclonal antibody (H2Mab-181) using enzyme-linked immunosorbent assay. *Monoclon Antib Immunodiagn Immunother* 2021;40:255–260; doi: 10.1089/mab.2021.0029
  34. Takei J, Asano T, Tanaka T, et al. Development of a novel anti-HER2 monoclonal antibody H2Mab-181 for gastric cancer. *Monoclon Antib Immunodiagn Immunother* 2021;40:168–176; doi: 10.1089/mab.2021.0021
  35. Li G, Ohishi T, Kaneko MK, et al. Defucosylated mouse-dog chimeric anti-EGFR antibody exerts antitumor activities in mouse xenograft models of canine tumors. *Cells* 2021;10(12):3599; doi: 10.3390/cells10123599
  36. Nanamiya R, Takei J, Ohishi T, et al. Defucosylated anti-epidermal growth factor receptor monoclonal antibody (134-mG2a-f) exerts antitumor activities in mouse xenograft models of canine osteosarcoma. *Monoclon Antib Immunodiagn Immunother* 2022;41:1–7; doi: 10.1089/mab.2021.0036
  37. Mizuno T, Kato Y, Kaneko MK, et al. Generation of a canine anti-canine CD20 antibody for canine lymphoma treatment. *Sci Rep* 2020;10:11476; doi: 10.1038/s41598-020-68470-9
  38. Nanamiya R, Suzuki H, Takei J, et al. Development of monoclonal antibody 281-mG2a-f against golden hamster podoplanin. *Monoclon Antib Immunodiagn Immunother* 2022; doi: 10.1089/mab.2021.0058
  39. Kawabata H, Ohishi T, Suzuki H, et al. A defucosylated mouse anti-CD10 monoclonal antibody (31-mG2a-f) exerts antitumor activity in a mouse xenograft model of renal cell cancers. *Monoclon Antib Immunodiagn Immunother* 2022; doi: 10.1089/mab.2021.0049
  40. Takei J, Kaneko MK, Ohishi T, et al. A defucosylated antiCD44 monoclonal antibody 5mG2af exerts antitumor effects in mouse xenograft models of oral squamous cell carcinoma. *Oncol Rep* 2020;44:1949–1960; doi: 10.3892/or.2020.7735
  41. Kawabata H, Suzuki H, Ohishi T, et al. A defucosylated mouse anti-CD10 monoclonal antibody (31-mG2a-f) exerts antitumor activity in a mouse xenograft model of CD10-overexpressed tumors. *Monoclon Antib Immunodiagn Immunother* 2022;41:59–66; doi: 10.1089/mab.2021.0048

42. Li G, Suzuki H, Takei J, et al. Antitumor activities in mouse xenograft models of canine mammary gland tumor by defucosylated mouse-dog chimeric anti-epidermal growth factor receptor antibody (E134Bf). *Monoclon Antib Immunodiagn Immunother* 2022;41:53–58; doi: 10.1089/mab.2021.0040
43. Takei J, Ohishi T, Kaneko MK, et al. A defucosylated anti-PD-L1 monoclonal antibody 13-mG2a-f exerts antitumor effects in mouse xenograft models of oral squamous cell carcinoma. *Biochem Biophys Rep* 2020;24:100801; doi: 10.1016/j.bbrep.2020.100801
44. Goto N, Suzuki H, Ohishi T, et al. Antitumor activities in mouse xenograft models of canine fibroblastic tumor by defucosylated anti-epidermal growth factor receptor monoclonal antibody. *Monoclon Antib Immunodiagn Immunother* 2022;41:67–73; doi: 10.1089/mab.2021.0059
45. Tateyama N, Nanamiya R, Ohishi T, et al. Defucosylated anti-epidermal growth factor receptor monoclonal antibody 134-mG2a-f exerts antitumor activities in mouse xenograft models of dog epidermal growth factor receptor-overexpressed cells. *Monoclon Antib Immunodiagn Immunother* 2021;40:177–183; doi: 10.1089/mab.2021.0022
46. Szewczyk M, Lechowski R, Zabielska K. What do we know about canine osteosarcoma treatment? Review. *Vet Res Commun* 2015;39:61–67; doi: 10.1007/s11259-014-9623-0
47. Selvarajah GT, Verheije MH, Kik M, et al. Expression of epidermal growth factor receptor in canine osteosarcoma: Association with clinicopathological parameters and prognosis. *Vet J* 2012;193:412–419; doi: 10.1016/j.tvjl.2012.02.009
48. Simpson S, Dunning MD, de Brot S, et al. Comparative review of human and canine osteosarcoma: Morphology, epidemiology, prognosis, treatment and genetics. *Acta Vet Scand* 2017;59:71; doi: 10.1186/s13028-017-0341-9
49. Boston SE, Ehrhart NP, Dernell WS, et al. Evaluation of survival time in dogs with stage III osteosarcoma that undergo treatment: 90 cases (1985–2004). *J Am Vet Med Assoc* 2006; 228:1905–1908; doi: 10.2460/javma.228.12.1905
50. Selmic LE, Burton JH, Thamm DH, et al. Comparison of carboplatin and doxorubicin-based chemotherapy protocols in 470 dogs after amputation for treatment of appendicular osteosarcoma. *J Vet Intern Med* 2014;28:554–563; doi: 10.1111/jvim.12313
51. Michels GM, Ramsey DS, Walsh KF, et al. A blinded, randomized, placebo-controlled, dose determination trial of lokivetmab (ZTS-00103289), a caninized, anti-canine IL-31 monoclonal antibody in client owned dogs with atopic dermatitis. *Vet Dermatol* 2016;27:478–e129; doi: 10.1111/vde.12376
52. Singer J, Weichselbaumer M, Stockner T, et al. Comparative oncology: ErbB-1 and ErbB-2 homologues in canine cancer are susceptible to cetuximab and trastuzumab targeting. *Mol Immunol* 2012;50:200–209; doi: 10.1016/j.molimm.2012.01.002
53. Dias JNR, Almeida A, Andre AS, et al. Characterization of the canine CD20 as a therapeutic target for comparative passive immunotherapy. *Sci Rep* 2022;12:2678; doi: 10.1038/s41598-022-06549-1
54. Maekawa N, Konnai S, Ikebuchi R, et al. Expression of PD-L1 on canine tumor cells and enhancement of IFN-gamma production from tumor-infiltrating cells by PD-L1 blockade. *PLoS One* 2014;9:e98415; doi: 10.1371/journal.pone.0098415

Address correspondence to:

*Yukinari Kato*  
*Department of Molecular Pharmacology*  
*Tohoku University Graduate School of Medicine*  
*2-1, Seiryomachi, Aoba-ku*  
*Sendai, Miyagi 980-8575*  
*Japan*

*E-mail: yukinari.kato.e6@tohoku.ac.jp*

*Received: May 24, 2022*

*Accepted: September 30, 2022*